<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Pharmacol</journal-id>
<journal-id journal-id-type="hwp">molpharm</journal-id>
<journal-id journal-id-type="pmc">Mol Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">MolPharm</journal-id>
<journal-title-group>
<journal-title>Molecular Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0026-895X</issn>
<issn pub-type="epub">1521-0111</issn>
<publisher>
<publisher-name>The American Society for Pharmacology and Experimental Therapeutics</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29895592</article-id>
<article-id pub-id-type="pmc">6041953</article-id>
<article-id pub-id-type="publisher-id">MOL_112359</article-id>
<article-id pub-id-type="doi">10.1124/mol.118.112359</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992<xref ref-type="fn" rid="FN3"><sup><inline-graphic xlink:href="sbox.jpg"></inline-graphic></sup></xref></article-title>
<alt-title alt-title-type="short">Kir4.1 Inhibitor: VU0134992</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kharade</surname>
<given-names>Sujay V.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kurata</surname>
<given-names>Haruto</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bender</surname>
<given-names>Aaron M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blobaum</surname>
<given-names>Anna L.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Figueroa</surname>
<given-names>Eric E.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duran</surname>
<given-names>Amanda</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kramer</surname>
<given-names>Meghan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Days</surname>
<given-names>Emily</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vinson</surname>
<given-names>Paige</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flores</surname>
<given-names>Daniel</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Satlin</surname>
<given-names>Lisa M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meiler</surname>
<given-names>Jens</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weaver</surname>
<given-names>C. David</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lindsley</surname>
<given-names>Craig W.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hopkins</surname>
<given-names>Corey R.</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Denton</surname>
<given-names>Jerod S.</given-names>
</name>
</contrib>
<aff id="aff1">Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee (S.V.K., M.K., J.S.D.); Center for Neuroscience Drug Discovery and the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (H.K., A.M.B., A.L.B., C.W.L., C.R.H.), Departments of Pharmacology (H.K., A.M.B., E.E.F., J.M., C.D.W., C.W.L., J.S.D.) and Chemistry (A.D., J.M., C.D.W., C.W.L.), High-Throughput Screening Center (E.D., P.V.), and Institute of Chemical Biology (C.D.W., C.W.L., J.S.D.), Vanderbilt University, Nashville, Tennessee; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York (D.F., L.M.S.); and Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska (C.R.H.)</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Address correspondence to:</bold> Dr. Jerod S. Denton, <addr-line>T4208 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232.</addr-line> E-mail: <email>jerod.s.denton@vanderbilt.edu</email>; or Dr. Corey Hopkins, <addr-line>Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, NE 68198-6125.</addr-line> E-mail: <email>corey.hopkins@unmc.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<month>8</month>
<year>2018</year>
</pub-date>
<volume>94</volume>
<issue>2</issue>
<fpage>926</fpage>
<lpage>937</lpage>
<history>
<date date-type="received">
<day>01</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<self-uri xlink:href="mol.118.112359.pdf" xlink:title="pdf"></self-uri>
<abstract>
<p>The inward rectifier potassium (Kir) channel Kir4.1 (<italic>KCNJ10</italic>) carries out important physiologic roles in epithelial cells of the kidney, astrocytes in the central nervous system, and stria vascularis of the inner ear. Loss-of-function mutations in <italic>KCNJ10</italic> lead to EAST/SeSAME syndrome, which is characterized by epilepsy, ataxia, renal salt wasting, and sensorineural deafness. Although genetic approaches have been indispensable for establishing the importance of Kir4.1 in the normal function of these tissues, the availability of pharmacological tools for acutely manipulating the activity of Kir4.1 in genetically normal animals has been lacking. We therefore carried out a high-throughput screen of 76,575 compounds from the Vanderbilt Institute of Chemical Biology library for small-molecule modulators of Kir4.1. The most potent inhibitor identified was 2-(2-bromo-4-isopropylphenoxy)-<italic>N</italic>-(2,2,6,6-tetramethylpiperidin-4-yl)acetamide (VU0134992). In whole-cell patch-clamp electrophysiology experiments, VU0134992 inhibits Kir4.1 with an IC<sub>50</sub> value of 0.97 <italic>µ</italic>M and is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC<sub>50</sub> = 9 <italic>µ</italic>M) at −120 mV. In thallium (Tl<sup>+</sup>) flux assays, VU0134992 is greater than 30-fold selective for Kir4.1 over Kir1.1, Kir2.1, and Kir2.2; is weakly active toward Kir2.3, Kir6.2/SUR1, and Kir7.1; and is equally active toward Kir3.1/3.2, Kir3.1/3.4, and Kir4.2. This potency and selectivity profile is superior to Kir4.1 inhibitors amitriptyline, nortriptyline, and fluoxetine. Medicinal chemistry identified components of VU0134992 that are critical for inhibiting Kir4.1. Patch-clamp electrophysiology, molecular modeling, and site-directed mutagenesis identified pore-lining glutamate 158 and isoleucine 159 as critical residues for block of the channel. VU0134992 displayed a large free unbound fraction (<italic>f</italic><sub>u</sub>) in rat plasma (<italic>f</italic><sub>u</sub> = 0.213). Consistent with the known role of Kir4.1 in renal function, oral dosing of VU0134992 led to a dose-dependent diuresis, natriuresis, and kaliuresis in rats. Thus, VU0134992 represents the first in vivo active tool compound for probing the therapeutic potential of Kir4.1 as a novel diuretic target for the treatment of hypertension.</p>
</abstract>
<counts>
<fig-count count="6"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="61"></ref-count>
<page-count count="12"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name> DJS Export </meta-name>
<meta-value>v1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>